Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lymphoma, non-Hodgkin lymphoma, child
Stage/Subtype:  stage II childhood lymphoblastic lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-23 of 23 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Age: 65 and under
Trial IDs: CB-AB006, NCI-2013-00758, 2012-0166, NCT01854567
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Phase: Phase II
Type: Treatment
Age: 45 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease
Phase: Phase II
Type: Treatment
Age: 6 months to 45 years
Trial IDs: 2010.00, NCI-2010-00190, FHCRC 2010.00, Protocol 2010, 6095, NCT00719888
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Combination Chemotherapy and Ofatumumab in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2010-0708, NCI-2011-01061, NCT01363128
Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: NHL16, NCI-2012-00496, SJCRH, NCT01451515
Calaspargase Pegol or Pegaspargase in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 365 days to 18 years
Trial IDs: 11-001, NCI-2012-00825, NCT01574274
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Treating Patients With Newly Diagnosed or Recurrent Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CAR CD30, NCI-2012-00640, H-26617, NCT01192464
Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Diseases
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: MALTED, NCI-2012-01079, H-28361, NCT01447056
Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: H-29617, NCI-2013-01016, GRALE, NCT01555892
Genetically Modified T-Cells in Treating Patients With Advanced Non-Hodgkin's Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: H-31970, NCI-2013-01017, H-31970 SAGAN, SAGAN, NCT01853631
Unrelated Donor Stem Cell Transplant in Treating Patients With Malignant and Non-Malignant Disorders
Phase: No phase specified
Type: Treatment
Age: 0 to 55
Trial IDs: AAAB3095, NCI-2011-00361, NCT01050439
Proton Beam Radiation Therapy in Treating Patients with Hodgkin and Non-Hodgkin Lymphoma Involving the Mediastinum
Phase: No phase specified
Type: Treatment
Age: 6 and over
Trial IDs: 12-346, NCI-2013-00625, NCT01751412
CD34+ Stem Cell Selection in Treating Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Start Over